Literature DB >> 6996969

Characteristics of glycemic stability.

F J Service, R L Nelson.   

Abstract

Glucose homeostasis in healthy subjects is characterized by postmeal glucose increases of about 40 mg/dl, peaks at about 45 min, decreases close to antecibal levels 1 h after the peak, and no spontaneous oscillations until the next meal. Diabetes is characterized by progressive loss of glucose homeostasis from stable to unstable, which is directly proportional to loss of insulin secretory reserve. Degree of instability of diabetes in ambulatory subjects within a 24-h period can be expressed as mean amplitude of glycemic excursion of M-value and between two successive 24-h periods as mean of daily differences of blood glucose. Stable diabetic persons have lower values, which are closest to those of nondiabetic persons, and unstable diabetic persons have higher values. The mean diurnal blood glucose level is a measure of glycemic control. The failure to restore glycemic patterns of diabetic to those of nondiabetic persons is largely due to the failure of subcutaneously administered insulin to mimic the pattern of insulinemia of healthy subjects.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6996969     DOI: 10.2337/diacare.3.1.58

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  29 in total

Review 1.  The challenges of measuring glycemic variability.

Authors:  David Rodbard
Journal:  J Diabetes Sci Technol       Date:  2012-05-01

2.  Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.

Authors:  Steven J Russell; Mallory A Hillard; Courtney Balliro; Kendra L Magyar; Rajendranath Selagamsetty; Manasi Sinha; Kerry Grennan; Debbie Mondesir; Laya Ekhlaspour; Hui Zheng; Edward R Damiano; Firas H El-Khatib
Journal:  Lancet Diabetes Endocrinol       Date:  2016-02-03       Impact factor: 32.069

3.  Outpatient glycemic control with a bionic pancreas in type 1 diabetes.

Authors:  Steven J Russell; Firas H El-Khatib; Manasi Sinha; Kendra L Magyar; Katherine McKeon; Laura G Goergen; Courtney Balliro; Mallory A Hillard; David M Nathan; Edward R Damiano
Journal:  N Engl J Med       Date:  2014-06-15       Impact factor: 91.245

4.  Glycemic instability of non-diabetic patients after spine surgery: a prospective cohort study.

Authors:  Jean Langlois; Benjamin Bouyer; Béatrice Larroque; Cyril Dauzac; Pierre Guigui
Journal:  Eur Spine J       Date:  2014-08-08       Impact factor: 3.134

5.  Parsimonious Description of Glucose Variability in Type 2 Diabetes by Sparse Principal Component Analysis.

Authors:  Chiara Fabris; Andrea Facchinetti; Giuseppe Fico; Francesco Sambo; Maria Teresa Arredondo; Claudio Cobelli
Journal:  J Diabetes Sci Technol       Date:  2015-07-31

6.  Glucose control in mobile type 1 (insulin-dependent) diabetic patients by means of a semi-automatic feedback controlled insulin infusion system.

Authors:  K Piwernetz; R Renner; K D Hepp
Journal:  Diabetologia       Date:  1982-09       Impact factor: 10.122

7.  Serum fructosamine concentration as measure of blood glucose control in type I (insulin dependent) diabetes mellitus.

Authors:  J R Baker; P A Metcalf; I M Holdaway; R N Johnson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-02

8.  New indices for predicting glycaemic variability.

Authors:  Akifumi Ogawa; Akinori Hayashi; Eriko Kishihara; Sonomi Yoshino; Akihiro Takeuchi; Masayoshi Shichiri
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

9.  Protection of pancreatic INS-1 β-cells from glucose- and fructose-induced cell death by inhibiting mitochondrial permeability transition with cyclosporin A or metformin.

Authors:  S Lablanche; C Cottet-Rousselle; F Lamarche; P-Y Benhamou; S Halimi; X Leverve; E Fontaine
Journal:  Cell Death Dis       Date:  2011-03-24       Impact factor: 8.469

10.  Glucose variability.

Authors:  F John Service
Journal:  Diabetes       Date:  2013-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.